Literature DB >> 19942257

Standardisation of thrombin generation test--which reference plasma for TGT? An international multicentre study.

Y Dargaud1, R Luddington, E Gray, T Lecompte, T Siegemund, T Baglin, J Hogwood, V Regnault, A Siegemund, C Negrier.   

Abstract

We have previously shown that standardisation and normalization of results improve the intercentre variability of the calibrated automated thrombin generation test (TGT). We suspected that the source of reference plasma (RP) might be a contributing factor to variability and compared 5 commercial RP and a RP provided by the NIBSC, in an international, multicentre study. The detailed composition of the 6 tested plasma samples was determined in the Haemostasis Laboratory in Lyon. The lot to lot consistency, intra-assay, inter-assay variability were calculated for all tested plasmas. The RP and 3 plasma samples (a normal control, a hypocoagulable and a hypercoagulable plasmas) were tested over 6 days, in 5 European centres. Results were normalised against each of the tested RP and intercentre variability of results was compared. All laboratories used the same reagents. Before normalization, the inter-centre variability was 19.8 to 27.3%. After normalization, we observed a significantly improved inter-laboratory variation with all tested RP, despite differences between them. These results clearly demonstrate that the inter-centre variability of TGT can be significantly reduced by using a reference plasma normalization, and that certain RP have a better capacity to reduce this variability than others. (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19942257     DOI: 10.1016/j.thromres.2009.11.012

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  23 in total

1.  Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent.

Authors:  Ruchika Sharma; Amanda P Waller; Shipra Agrawal; Katelyn J Wolfgang; Hiep Luu; Khurrum Shahzad; Berend Isermann; William E Smoyer; Marvin T Nieman; Bryce A Kerlin
Journal:  J Am Soc Nephrol       Date:  2017-04-19       Impact factor: 10.121

2.  Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome.

Authors:  Bryce A Kerlin; Amanda P Waller; Ruchika Sharma; Melinda A Chanley; Marvin T Nieman; William E Smoyer
Journal:  J Am Soc Nephrol       Date:  2015-04-08       Impact factor: 10.121

3.  Thrombin generation test as a marker for high risk venous thrombosis pregnancies.

Authors:  Bérangère S Joly; Bénédicte Sudrié-Arnaud; Virginie Barbay; Jeanne-Yvonne Borg; Véronique Le Cam Duchez
Journal:  J Thromb Thrombolysis       Date:  2018-01       Impact factor: 2.300

4.  Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH.

Authors:  Y Dargaud; A S Wolberg; E Gray; C Negrier; H C Hemker
Journal:  J Thromb Haemost       Date:  2017-06-28       Impact factor: 5.824

5.  Applicability of the Thrombin Generation Test to Evaluate the Hemostatic Status of Hemophilia A Patients in Daily Clinical Practice.

Authors:  Ángel Bernardo; Alberto Caro; Daniel Martínez-Carballeira; José Ramón Corte; Sonia Vázquez; Carmen Palomo-Antequera; Alfredo Andreu; Álvaro Fernández-Pardo; Julia Oto; Laura Gutiérrez; Inmaculada Soto; Pilar Medina
Journal:  J Clin Med       Date:  2022-06-10       Impact factor: 4.964

Review 6.  Global assays of hemostasis.

Authors:  Kathleen E Brummel-Ziedins; Alisa S Wolberg
Journal:  Curr Opin Hematol       Date:  2014-09       Impact factor: 3.284

7.  Characterization of the hypercoagulable state in patients with sickle cell disease.

Authors:  Nirmish Shah; Courtney Thornburg; Marilyn J Telen; Thomas L Ortel
Journal:  Thromb Res       Date:  2012-09-07       Impact factor: 3.944

8.  Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy.

Authors:  Amanda P Waller; Jonathan P Troost; Samir V Parikh; Katelyn J Wolfgang; Brad H Rovin; Marvin T Nieman; William E Smoyer; Matthias Kretzler; Bryce A Kerlin
Journal:  Thromb Res       Date:  2021-02-16       Impact factor: 3.944

9.  Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.

Authors:  H Cohen; C J Doré; S Clawson; B J Hunt; D Isenberg; M Khamashta; N Muirhead
Journal:  Lupus       Date:  2015-05-04       Impact factor: 2.911

10.  Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.

Authors:  Hannah Cohen; Beverley J Hunt; Maria Efthymiou; Deepa R J Arachchillage; Ian J Mackie; Simon Clawson; Yvonne Sylvestre; Samuel J Machin; Maria L Bertolaccini; Maria Ruiz-Castellano; Nicola Muirhead; Caroline J Doré; Munther Khamashta; David A Isenberg
Journal:  Lancet Haematol       Date:  2016-09       Impact factor: 18.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.